To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • FAQs

    Tumor Ablation Market size was valued at USD 2.17 Billion in 2024 and is poised to grow from USD 2.48 Billion in 2025 to USD 7.17 Billion by 2033, growing at a CAGR of 14.2% during the forecast period (2026–2033).

    Tumor ablation providers around the world are estimated to focus on research to maximize their business potential and stay competitive. Developing new therapeutics for specific cancer indications will also be a preferred strategy for new as well as leading tumor ablation companies. Market players can also benefit from government support to take their oncology research capabilities to the next level. Use of advanced drug discovery and development techniques will also be popular among tumor ablation providers in the future.  'Medtronic plc (Ireland)', 'Boston Scientific Corporation (USA) ', 'Johnson & Johnson (USA) ', 'Abbott Laboratories (USA) ', 'Varian Medical Systems, Inc. (USA) ', 'Olympus Corporation (Japan) ', 'AngioDynamics, Inc. (USA) ', 'Terumo Corporation (Japan) ', 'Siemens Healthineers AG (Germany) ', 'Merit Medical Systems, Inc. (USA) ', 'EDAP TMS S.A. (France) ', 'Stryker Corporation (USA) ', 'Hologic, Inc. (USA) ', 'IceCure Medical Ltd. (Israel) ', 'Galil Medical, Inc. (USA) ', 'ConMed Corporation (USA) ', 'Neuwave Medical, Inc. (USA) ', 'SonaCare Medical LLC. (USA) ', 'Mermaid Medical A/S (Denmark)'

    Prevalence of cancer around the world is increasing at a rapid pace and this is projected to be a key factor driving up the demand for tumor ablation over the coming years. Tumor ablation is used for minimally invasive treatment of liver, lung, and kidney cancers and is especially popular among patients unfit for surgery. 

    North America is estimated to secure the top spot when it comes to the global tumor ablation market forecast. The presence of a developed healthcare ecosystem, quick adoption of minimally invasive treatment technologies, and high investments in oncology R&D are expected to be key factors promoting the demand for tumor ablation in North America going forward. The United States is estimated to be the leading market for tumor ablation companies in this region owing to high incidence of different types of cancers and rising healthcare expenditure. Canada is also projected to create new opportunities for tumor ablation providers operation in this region. 

    Feedback From Our Clients

    Global Tumor Ablation Market

    Report ID: SQMIG35A2494

    $5,300
    BUY NOW